期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

乳腺癌术后辅助化疗的进展 被引量：7

Advances in Postoperative Adjuvant Chemotherapy for Breast Cancer
暂未订购
导出
摘要 辅助化疗是乳腺癌综合治疗中的重要组成部分,也是预防远处转移的主要手段。本文对近年来乳腺癌术后辅助化疗进展的相关文献进行了回顾,在内科治疗方面,规范化、个体化是乳腺癌辅助治疗的方向。 Adjuvant chemotherapy is a major part of comprehensive treatment for breast cancer, and it is also paramount for preventing distal metastasis of the breast cancer. Recent data for postoperative adjuvant chemotherapy for breast cancer were reviewed in this article. Standardization and individualization of medical treatment may be of significance in directing adjuvant therapy for breast cancer.
作者 佟仲生 李淑芬
机构地区 天津医科大学附属肿瘤医院肿瘤内二科乳腺癌防治教育部重点实验室
出处 《中国肿瘤临床》 CAS CSCD 北大核心 2007年第13期772-775,共4页 Chinese Journal of Clinical Oncology
关键词 乳腺癌 综合治疗 辅助化疗 Breast cancer Compositive therapy Adjuvant chemotherapy
分类号 R737.9 [医药卫生—肿瘤]
  • 相关文献

参考文献14

  • 1Bonadonna G,Moliterni A,Zambetti M,et al.30 years' follow up of randomised studies of adjuvant CMF in operable breast cancer:cohort study[J].BMJ,2005,330(7485):217-220
  • 2孙燕.乳腺癌综合治疗的进展.临床肿瘤学现状,2005,2(1):2-3.
  • 3Fisher B,Brown AM,Dimitrov NV,et al.Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide,methotrexate,and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors:results from the National Surgical Adjuvant Breast and Bowel Project B-15[J].J Clin Oncol,1990,8(9):1483-1496
  • 4Early Breast Cancer Trialists' Collaborative Group (EBCTCG).Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival:an overview of the randomised trials[J].Lancet,2005,365(9472):1687-1717
  • 5Levine MN,Pritchard KI,Bramwell VH,et al.Randomized trial comparing cyclophosphamide,epirubicin,and fluorouracil with cyclophosphamide,methotrexate,and fluorouracil in premenopausal women with node-positive breast cancer:update of National Cancer Institute of Canada Clinical Trials Group Trial MA5[J].J Clin Oncol,2005,23(22):5166-5170
  • 6Henderson IC,Berry DA,Demetri GD,et al.Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer[J].J Clin Oncol,2003,21(6):976-983
  • 7Mamounas EP,Bryant J,Lembersky B,et al.Paclitaxel after doxorubicin plus cydophosphamide as adjuvant chemotherapy for node-positive breast cancer:results from NSABP B-28[J].J Clin Oncol,2005,23(16):3686-3696
  • 8Martin M,Pienkowski T,Mackey J,et al.Adjuvant docetaxel for node-positive breast cancer[J].N Engl J Med,2005,352(22):2302-2313
  • 9Smith I.Adjuvant treatment for early breast cancer[J].Ann Oncol,2005,16(Suppl 2):182-187
  • 10Cold S,During M,Ewertz M,et al.Does timing of adjuvant chemotherapy influence the prognosis after early breast cancer?Results of the Danish Breast Cancer Cooperative Group (DBCG)[J].Br J Cancer,2005,93(6):627-632

同被引文献44

  • 1江泽飞,宋三泰.蒽环类化疗药物治疗乳腺癌的新动向[J].中华肿瘤杂志,2005,27(4):193-195. 被引量：28
  • 2邓敏,施勤,顾永平,谢芳,张学光.CD40、P53在乳腺癌中的表达和生物学意义[J].中国现代医药杂志,2006,8(1):36-38. 被引量：2
  • 3杨玲,李连弟,陈育德,D.M.Parkin.中国乳腺癌发病死亡趋势的估计与预测[J].中华肿瘤杂志,2006,28(6):438-440. 被引量：281
  • 4Inman BA, Frigola X, Dong H, et al. Costimulafion,coinhibition and cancer[J]. Curt Cancer Drug Targets, 2007, 7(1): 15-30.
  • 5Voorzanger-Rousselot N, Blay JY. Coexpression of CD40 and CD40L on B lymphoma and carcinoma cells:an antocrinc anti-apoptotic role[J]. Leuk Lymphoma, 2004, 45(6): 1239-1245.
  • 6Salvatorelli E, Menna P, Cascegna S, et al. Paclitaxel and docetax el stimulation of doxorubicinol formation in the human heart: implications for cardiotoxicity of doxorubicin-taxane chemothera pies[J]. J Pharmacol Exp Ther, 2006, 318(1): 424-433
  • 7von Minckwitz G. Docetaxel/anthracycline combinations for breast cancer treatment[J]. Expert Opin Pharmacother, 2007, 8(4): 485-495.
  • 8Melichar B, Patenia R, Gallardo S, et al. Expression of CD40 and growth-inhibitory activity of CD40 hgand in ovarian cancer cell lines[J]. Gynecol Oncol, 2007, 104(3): 707-713.
  • 9Bradshaw-Pierce EL, Steinhauer CA, Raben D, et al. Pharmacokinetic-directed dosing of vandetanib and docetaxel in a mouse model of human squamous cell carcinoma[J]. Mol Cancer Ther, 2008, 7(9): 3006-3017.
  • 10Kincaid EH,Davis PW,Chang MC,et al."Blind" placement of longterm central venous access devices:report of 589 consecutive procedures[J].The American surgeon,1999,65(6):520.

引证文献7

二级引证文献15

中国肿瘤临床
2007年 第13期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部